(Q33645696)

28 July 2017

1 reference

title

Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease (English)

1 reference

28 July 2017

coronary artery disease

1 reference

Hay JW

1

1 reference

28 July 2017

Yu WM

series ordinal

2

1 reference

28 July 2017

Ashraf T

series ordinal

3

1 reference

28 July 2017

1 January 1999

1 reference

28 July 2017

1 reference

28 July 2017

15

1 reference

28 July 2017

47-74

1 reference

28 July 2017

1

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-199915010-00004

28 July 2017

0 references

cites work

Differences in the treatment of myocardial infarction between the United States and Canada. A survey of physicians in the GUSTO trial

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

The risk of myocardial infarction associated with antihypertensive drug therapies

1 reference

12 December 2020

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

12 December 2020

Economics of lipid lowering with HMG CoA reductase inhibitors

1 reference

12 December 2020

Cost-effective care of end-stage renal disease: a billion dollar question

1 reference

12 December 2020

Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study.

1 reference

12 December 2020

Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group

1 reference

12 December 2020

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Cost-effectiveness analysis in heart disease, Part I: General principles

1 reference

12 December 2020

Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study.

1 reference

12 December 2020

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

1 reference

12 December 2020

Cost of lipid-lowering statin drugs

1 reference

12 December 2020

Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial

1 reference

12 December 2020

Lipids and risk of coronary heart disease. The Framingham Study

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Five-hundred life-saving interventions and their cost-effectiveness

1 reference

12 December 2020

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation

1 reference

12 December 2020

Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

1 reference

12 December 2020

A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia

1 reference

12 December 2020

Relative impact of targeted versus populationwide cholesterol interventions on the incidence of coronary heart disease. Projections of the Coronary Heart Disease Policy Model

1 reference

12 December 2020

Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel.

1 reference

12 December 2020

Outcome assessment in cardiovascular cost-benefit studies

1 reference

12 December 2020

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

12 December 2020

Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study

1 reference

12 December 2020

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

1 reference

12 December 2020

Prevention of heart disease: is LDL reduction the outcome of choice? No, there is more.

1 reference

12 December 2020

Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands

1 reference

12 December 2020

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

12 December 2020

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

1 reference

12 December 2020

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

1 reference

12 December 2020

The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle

1 reference

12 December 2020

Medical costs of coronary artery disease in the United States.

1 reference

12 December 2020

Cholesterol, children, and heart disease: an analysis of alternatives

1 reference

12 December 2020

The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin

1 reference

12 December 2020

An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction

1 reference

12 December 2020

Effect of itraconazole on the pharmacokinetics of atorvastatin

1 reference

12 December 2020

Colestipol hydrochloride in hypercholesterolemic patients—Effect on serum cholesterol and mortality

1 reference

12 December 2020

The 4S study and its pharmacoeconomic implications

1 reference

12 December 2020

Oat-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations of hypercholesterolemic men

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction.

1 reference

12 December 2020

Cholesterol-lowering intervention program. Effect of the step I diet in community office practices

1 reference

12 December 2020

Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved

1 reference

12 December 2020

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

1 reference

12 December 2020

Trends in acute myocardial infarction and coronary heart disease death in the United States

1 reference

12 December 2020

Cost-effectiveness of interventions to prevent or treat coronary heart disease

1 reference

12 December 2020

Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study

1 reference

12 December 2020

The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.

1 reference

12 December 2020

Cost-effectiveness analysis of end-stage renal disease treatments

1 reference

12 December 2020

Medical Care Costs and Quality of Life after Randomization to Coronary Angioplasty or Coronary Bypass Surgery

1 reference

12 December 2020

Valvular heart disease associated with fenfluramine-phentermine

1 reference

12 December 2020

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

12 December 2020

Principles of pharmacoeconomic analysis of drug therapy

1 reference

12 December 2020

Antiarrhythmic prophylaxis after acute myocardial infarction. Is lidocaine still useful?

1 reference

12 December 2020

Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.

1 reference

12 December 2020

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

12 December 2020

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

1 reference

12 December 2020

Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management

1 reference

12 December 2020

The cost effectiveness of lipid lowering in Swedish primary health care. The CELL Study Group

1 reference

12 December 2020

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

12 December 2020

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

1 reference

12 December 2020

Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor

1 reference

12 December 2020

Review of lipid-lowering clinical trials in relation to observational epidemiologic studies

1 reference

12 December 2020

Foundations of Cost-Effectiveness Analysis for Health and Medical Practices

1 reference

12 December 2020

Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)

1 reference

12 December 2020

Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials

1 reference

12 December 2020

Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization

1 reference

12 December 2020

Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989.

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy

1 reference

12 December 2020

Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients

1 reference

12 December 2020

Hypercholesterolemia: the cost of treatment in perspective

1 reference

12 December 2020

Economic modeling and sensitivity analysis.

1 reference

12 December 2020

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

1 reference

12 December 2020

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

12 December 2020

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

1 reference

12 December 2020

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

1 reference

12 December 2020

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.

1 reference

12 December 2020

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

1 reference

12 December 2020

Cost-effectiveness of coronary artery bypass surgery

1 reference

12 December 2020

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine

1 reference

12 December 2020

Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.

1 reference

12 December 2020

Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial.

1 reference

12 December 2020

Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia

1 reference

12 December 2020

10.2165/00019053-199915010-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference